Mab Vax Therapeutics
Biotechnology, Sorrento Vly Rd, San Diego, , 92121, California, 11535, United States, 11-50 Employees
Phone Number: 18*********
Who is MABVAX THERAPEUTICS
MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of p...
Read More
-
Headquarters: 11535 Sorrento Vly Rd, San Diego, California, 92121, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 551112 |
Show More
Does something look wrong? Fix it. | View contact records from MABVAX THERAPEUTICS
MabVax Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding MabVax Therapeutics
Answer: MabVax Therapeutics's headquarters are located at Sorrento Vly Rd, San Diego, , 92121, California, 11535, United States
Answer: MabVax Therapeutics's phone number is 18*********
Answer: MabVax Therapeutics's official website is https://mabvax.com
Answer: MabVax Therapeutics's revenue is $5 Million to $10 Million
Answer: MabVax Therapeutics's SIC: 2834
Answer: MabVax Therapeutics's NAICS: 551112
Answer: MabVax Therapeutics has 11-50 employees
Answer: MabVax Therapeutics is in Biotechnology
Answer: MabVax Therapeutics contact info: Phone number: 18********* Website: https://mabvax.com
Answer: MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety, specificity for the target and a potential efficacy signal. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month